Global Biosimilars Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025
The Global Biosimilars Market is expected to grow from USD 6,738.14 Million in 2018 to USD 28,903.56 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 23.12%.
The positioning of the Global Biosimilars Market vendors in FPNV Positioning Matrix are determined by Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinders, N: Niche, and V: Vital).
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Biosimilars Market including are Amgen Inc., Biogen Inc., Dr. Reddy's Laboratories Limited, Mylan N.V., Pfizer Inc., Sandoz International GmbH, AMEGA Biotech S.A., Apotex Inc., Biogen Inc., Biosidus S.A., Bioton S.A., Dr. Reddy's Laboratories Limited, Innovent Biologics, Inc., JHL Biotech, Inc., LG Chem, Ltd., and Merck Sharp & Dohme Corp..
On the basis of Indication, the Global Biosimilars Market is studied across Autoimmune Diseases, Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Infectious Diseases, and Oncology.
On the basis of Product, the Global Biosimilars Market is studied across Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, and Recombinant Peptides.
On the basis of Manufacturing, the Global Biosimilars Market is studied across Contract Manufacturing and In-House Manufacturing.
For the detailed coverage of the study, the market has been geographically divided into the Americas, Asia-Pacific, and Europe, Middle East & Africa. The report provides details of qualitative and quantitative insights about the major countries in the region and taps the major regional developments in detail.
In the report, we have covered two proprietary models, the FPNV Positioning Matrix and Competitive Strategic Window. The FPNV Positioning Matrix analyses the competitive market place for the players in terms of product satisfaction and business strategy they adopt to sustain in the market. The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisitions strategies, geography expansion, research & development, new product introduction strategies to execute further business expansion and growth.
Research Methodology:
Our market forecasting is based on a market model derived from market connectivity, dynamics, and identified influential factors around which assumptions about the market are made. These assumptions are enlightened by fact-bases, put by primary and secondary research instruments, regressive analysis and an extensive connect with industry people. Market forecasting derived from in-depth understanding attained from future market spending patterns provides quantified insight to support your decision-making process. The interview is recorded, and the information gathered in put on the drawing board with the information collected through secondary research.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on sulfuric acid offered by the key players in the Global Biosimilars Market
2. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments in the Global Biosimilars Market
3. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets for the Global Biosimilars Market
4. Market Diversification: Provides detailed information about new products launches, untapped geographies, recent developments, and investments in the Global Biosimilars Market
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players in the Global Biosimilars Market
The report answers questions such as:
1. What is the market size of Biosimilars market in the Global?
2. What are the factors that affect the growth in the Global Biosimilars Market over the forecast period?
3. What is the competitive position in the Global Biosimilars Market?
4. Which are the best product areas to be invested in over the forecast period in the Global Biosimilars Market?
5. What are the opportunities in the Global Biosimilars Market?
6. What are the modes of entering the Global Biosimilars Market?
The positioning of the Global Biosimilars Market vendors in FPNV Positioning Matrix are determined by Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinders, N: Niche, and V: Vital).
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Biosimilars Market including are Amgen Inc., Biogen Inc., Dr. Reddy's Laboratories Limited, Mylan N.V., Pfizer Inc., Sandoz International GmbH, AMEGA Biotech S.A., Apotex Inc., Biogen Inc., Biosidus S.A., Bioton S.A., Dr. Reddy's Laboratories Limited, Innovent Biologics, Inc., JHL Biotech, Inc., LG Chem, Ltd., and Merck Sharp & Dohme Corp..
On the basis of Indication, the Global Biosimilars Market is studied across Autoimmune Diseases, Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Infectious Diseases, and Oncology.
On the basis of Product, the Global Biosimilars Market is studied across Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, and Recombinant Peptides.
On the basis of Manufacturing, the Global Biosimilars Market is studied across Contract Manufacturing and In-House Manufacturing.
For the detailed coverage of the study, the market has been geographically divided into the Americas, Asia-Pacific, and Europe, Middle East & Africa. The report provides details of qualitative and quantitative insights about the major countries in the region and taps the major regional developments in detail.
In the report, we have covered two proprietary models, the FPNV Positioning Matrix and Competitive Strategic Window. The FPNV Positioning Matrix analyses the competitive market place for the players in terms of product satisfaction and business strategy they adopt to sustain in the market. The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisitions strategies, geography expansion, research & development, new product introduction strategies to execute further business expansion and growth.
Research Methodology:
Our market forecasting is based on a market model derived from market connectivity, dynamics, and identified influential factors around which assumptions about the market are made. These assumptions are enlightened by fact-bases, put by primary and secondary research instruments, regressive analysis and an extensive connect with industry people. Market forecasting derived from in-depth understanding attained from future market spending patterns provides quantified insight to support your decision-making process. The interview is recorded, and the information gathered in put on the drawing board with the information collected through secondary research.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on sulfuric acid offered by the key players in the Global Biosimilars Market
2. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments in the Global Biosimilars Market
3. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets for the Global Biosimilars Market
4. Market Diversification: Provides detailed information about new products launches, untapped geographies, recent developments, and investments in the Global Biosimilars Market
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players in the Global Biosimilars Market
The report answers questions such as:
1. What is the market size of Biosimilars market in the Global?
2. What are the factors that affect the growth in the Global Biosimilars Market over the forecast period?
3. What is the competitive position in the Global Biosimilars Market?
4. Which are the best product areas to be invested in over the forecast period in the Global Biosimilars Market?
5. What are the opportunities in the Global Biosimilars Market?
6. What are the modes of entering the Global Biosimilars Market?
1. PREFACE
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. RESEARCH & FORECASTING
2.1. Research Methodology
2.1.1. Research Process
2.1.2. Research Framework
2.1.3. Research Reliability & Validity
2.1.4. Research Assumptions
2.2. Forecasting Methodology
2.3. Research Outcome
2.3.1. 360iResearch Competitive Strategic Window
2.3.1.1. Leverage Zone
2.3.1.2. Vantage Zone
2.3.1.3. Speculative Zone
2.3.1.4. Bottleneck Zone
2.3.2. 360iResearch FPNV Positioning Matrix
2.3.2.1. 360iResearch Quadrants
2.3.2.1.1. Forefront
2.3.2.1.2. Pathfinders
2.3.2.1.3. Niche
2.3.2.1.4. Vital
2.3.2.2. Business Strategy
2.3.2.2.1. Business Growth
2.3.2.2.2. Industry Coverage
2.3.2.2.3. Financial Viability
2.3.2.2.4. Channel Support
2.3.2.3. Product Satisfaction
2.3.2.3.1. Value for Money
2.3.2.3.2. Ease of Use
2.3.2.3.3. Product Features
2.3.2.3.4. Customer Support
3. EXECUTIVE SUMMARY
3.1. Outlook in the Biosimilars Market
3.1.1. Since, 2006 when the first biosimilar has been introduced in the market, oncology has always remained the most focussed area for the development of biosimilars and has represented a huge impact on the treatment of cancer in multiple tumor types.
3.1.2. The players in the Biosimilar market are working at a feverish pace to develop the next generation of follow-on products.
3.1.3. Development of Recombinant Glycosylated Proteins category of biosimilars has always dominated the global market during the forecast period.
3.1.4. he Biosimilar market in Europe, Middle East, And Africa represent a dominating space during the forecast period.
3.1.5. Sandoz to resubmit biosimilar pegfilgrastim application to US FDA
3.1.6. Merck to acquire Immune Design
3.2. Opportunities in the Biosimilars Market
4. PREMIUM INSIGHT
4.1. Market Connectivity
4.2. Market Dynamics
4.2.1. Drivers
4.2.1.1. Growing pressure to reduce healthcare expenditure
4.2.1.2. Growing demands of pharmaceutical drugs
4.2.1.3. Expiration of major patents during the forecast period
4.2.1.4. Supportive government initiative and awareness creating programs in the developing economies
4.2.1.5. Lower cost biosimilars drugs than original biologics
4.2.2. Restraints
4.2.2.1. Reluctance of physicians to prescribe biosimilars
4.2.2.2. Unawareness among patients and preference for brand
4.2.3. Opportunities
4.2.3.1. New indications and patent expiry of biologic products
4.2.3.2. Potential in emerging markets
4.2.3.3. Emergence of bio-betters drugs
4.2.4. Challenges
4.2.4.1. Stringent regulatory requirements adversely affecting investment in the biosimilars market
4.2.4.2. High investment required for research and development
4.3. Porter’s Five Forces Analysis
4.3.1. Threat of New Entrants
4.3.2. Threat of Substitutes
4.3.3. Bargaining Power of Customers
4.3.4. Bargaining Power of Suppliers
4.3.5. Industry Rivalry
4.4. Industry Trends
4.4.1. Technical Development & Trends
4.4.2. Regulatory Submissions Timelines
4.4.3. Clinical Bio Analytics and Technical Timelines and Related FTEs
4.4.4. Drugs Loosing Patent: 2018-2022
5. GLOBAL BIOSIMILARS MARKET, BY INDICATION
5.1. Overview
5.2. Market Sizing & Forecasting
5.3. Autoimmune Diseases
5.4. Blood Disorders
5.5. Chronic Diseases
5.6. Growth Hormone Deficiency
5.7. Infectious Diseases
5.8. Oncology
6. GLOBAL BIOSIMILARS MARKET, BY PRODUCT
6.1. Overview
6.2. Market Sizing & Forecasting
6.3. Recombinant Glycosylated Proteins
6.3.1. Erythropoietin
6.3.2. Follitropin
6.3.3. Monoclonal Antibodies
6.3.3.1. Adalimumab
6.3.3.2. Infliximab
6.3.3.3. Rituximab
6.4. Recombinant Non-Glycosylated Proteins
6.4.1. Granulocyte Colony-Stimulating Factor
6.4.2. Insulin
6.4.3. Interferons
6.4.3.1. Interferon-Alpha
6.4.3.2. Interferon-Beta
6.4.4. Recombinant Human Growth Hormone
6.5. Recombinant Peptides
6.5.1. Calcitonin
6.5.2. Glucagon
7. GLOBAL BIOSIMILARS MARKET, BY MANUFACTURING
7.1. Overview
7.2. Market Sizing & Forecasting
7.3. Contract Manufacturing
7.4. In-House Manufacturing
8. GLOBAL BIOSIMILARS MARKET, BY GEOGRAPHY
8.1. Overview
8.2. Market Sizing & Forecasting
8.3. Americas
8.3.1. Overview
8.3.2. Market Sizing & Forecasting
8.3.3. Argentina
8.3.4. Brazil
8.3.5. Canada
8.3.6. Mexico
8.3.7. United States
8.4. Asia-Pacific
8.4.1. Overview
8.4.2. Market Sizing & Forecasting
8.4.3. Australia
8.4.4. China
8.4.5. India
8.4.6. Japan
8.5. Europe, Middle East & Africa
8.5.1. Overview
8.5.2. Market Sizing & Forecasting
8.5.3. France
8.5.4. Germany
8.5.5. Italy
8.5.6. Spain
8.5.7. United Kingdom
9. COMPETITIVE LANDSCAPE
9.1. 360iResearch FPNV Positioning Matrix for Global Biosimilars Market
9.2. Market Vendor Ranking Analysis for Global Biosimilars Market
9.3. Competitive News Feed Analysis for Global Biosimilars Market
10. COMPANY USABILITY PROFILES
10.1. Amgen Inc.
10.1.1. Overview
10.1.2. Strategy
10.1.3. SWOT
10.2. Biogen Inc.
10.2.1. Overview
10.2.2. Strategy
10.2.3. SWOT
10.3. Dr. Reddy's Laboratories Limited
10.3.1. Overview
10.3.2. Strategy
10.3.3. SWOT
10.4. Mylan N.V.
10.4.1. Overview
10.4.2. Strategy
10.4.3. SWOT
10.5. Pfizer Inc.
10.5.1. Overview
10.5.2. Strategy
10.5.3. SWOT
10.6. Sandoz International GmbH
10.6.1. Overview
10.6.2. Strategy
10.6.3. SWOT
10.7. AMEGA Biotech S.A.
10.8. Apotex Inc.
10.9. Biogen Inc.
10.10. Biosidus S.A.
10.11. Bioton S.A.
10.12. Dr. Reddy's Laboratories Limited
10.13. Innovent Biologics, Inc.
10.14. JHL Biotech, Inc.
10.15. LG Chem, Ltd.
10.16. Merck Sharp & Dohme Corp.
11. APPENDIX
11.1. Discussion Guide
11.2. Top Reports
11.2.1. Global Crane Rental Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025
11.2.2. Global Computer Vision Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025
11.2.3. Global Payment Gateway Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025
11.2.4. Global B2B Travel Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025
11.2.5. Global Varicose Vein Treatment Devices Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025
11.3. Author Details
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. RESEARCH & FORECASTING
2.1. Research Methodology
2.1.1. Research Process
2.1.2. Research Framework
2.1.3. Research Reliability & Validity
2.1.4. Research Assumptions
2.2. Forecasting Methodology
2.3. Research Outcome
2.3.1. 360iResearch Competitive Strategic Window
2.3.1.1. Leverage Zone
2.3.1.2. Vantage Zone
2.3.1.3. Speculative Zone
2.3.1.4. Bottleneck Zone
2.3.2. 360iResearch FPNV Positioning Matrix
2.3.2.1. 360iResearch Quadrants
2.3.2.1.1. Forefront
2.3.2.1.2. Pathfinders
2.3.2.1.3. Niche
2.3.2.1.4. Vital
2.3.2.2. Business Strategy
2.3.2.2.1. Business Growth
2.3.2.2.2. Industry Coverage
2.3.2.2.3. Financial Viability
2.3.2.2.4. Channel Support
2.3.2.3. Product Satisfaction
2.3.2.3.1. Value for Money
2.3.2.3.2. Ease of Use
2.3.2.3.3. Product Features
2.3.2.3.4. Customer Support
3. EXECUTIVE SUMMARY
3.1. Outlook in the Biosimilars Market
3.1.1. Since, 2006 when the first biosimilar has been introduced in the market, oncology has always remained the most focussed area for the development of biosimilars and has represented a huge impact on the treatment of cancer in multiple tumor types.
3.1.2. The players in the Biosimilar market are working at a feverish pace to develop the next generation of follow-on products.
3.1.3. Development of Recombinant Glycosylated Proteins category of biosimilars has always dominated the global market during the forecast period.
3.1.4. he Biosimilar market in Europe, Middle East, And Africa represent a dominating space during the forecast period.
3.1.5. Sandoz to resubmit biosimilar pegfilgrastim application to US FDA
3.1.6. Merck to acquire Immune Design
3.2. Opportunities in the Biosimilars Market
4. PREMIUM INSIGHT
4.1. Market Connectivity
4.2. Market Dynamics
4.2.1. Drivers
4.2.1.1. Growing pressure to reduce healthcare expenditure
4.2.1.2. Growing demands of pharmaceutical drugs
4.2.1.3. Expiration of major patents during the forecast period
4.2.1.4. Supportive government initiative and awareness creating programs in the developing economies
4.2.1.5. Lower cost biosimilars drugs than original biologics
4.2.2. Restraints
4.2.2.1. Reluctance of physicians to prescribe biosimilars
4.2.2.2. Unawareness among patients and preference for brand
4.2.3. Opportunities
4.2.3.1. New indications and patent expiry of biologic products
4.2.3.2. Potential in emerging markets
4.2.3.3. Emergence of bio-betters drugs
4.2.4. Challenges
4.2.4.1. Stringent regulatory requirements adversely affecting investment in the biosimilars market
4.2.4.2. High investment required for research and development
4.3. Porter’s Five Forces Analysis
4.3.1. Threat of New Entrants
4.3.2. Threat of Substitutes
4.3.3. Bargaining Power of Customers
4.3.4. Bargaining Power of Suppliers
4.3.5. Industry Rivalry
4.4. Industry Trends
4.4.1. Technical Development & Trends
4.4.2. Regulatory Submissions Timelines
4.4.3. Clinical Bio Analytics and Technical Timelines and Related FTEs
4.4.4. Drugs Loosing Patent: 2018-2022
5. GLOBAL BIOSIMILARS MARKET, BY INDICATION
5.1. Overview
5.2. Market Sizing & Forecasting
5.3. Autoimmune Diseases
5.4. Blood Disorders
5.5. Chronic Diseases
5.6. Growth Hormone Deficiency
5.7. Infectious Diseases
5.8. Oncology
6. GLOBAL BIOSIMILARS MARKET, BY PRODUCT
6.1. Overview
6.2. Market Sizing & Forecasting
6.3. Recombinant Glycosylated Proteins
6.3.1. Erythropoietin
6.3.2. Follitropin
6.3.3. Monoclonal Antibodies
6.3.3.1. Adalimumab
6.3.3.2. Infliximab
6.3.3.3. Rituximab
6.4. Recombinant Non-Glycosylated Proteins
6.4.1. Granulocyte Colony-Stimulating Factor
6.4.2. Insulin
6.4.3. Interferons
6.4.3.1. Interferon-Alpha
6.4.3.2. Interferon-Beta
6.4.4. Recombinant Human Growth Hormone
6.5. Recombinant Peptides
6.5.1. Calcitonin
6.5.2. Glucagon
7. GLOBAL BIOSIMILARS MARKET, BY MANUFACTURING
7.1. Overview
7.2. Market Sizing & Forecasting
7.3. Contract Manufacturing
7.4. In-House Manufacturing
8. GLOBAL BIOSIMILARS MARKET, BY GEOGRAPHY
8.1. Overview
8.2. Market Sizing & Forecasting
8.3. Americas
8.3.1. Overview
8.3.2. Market Sizing & Forecasting
8.3.3. Argentina
8.3.4. Brazil
8.3.5. Canada
8.3.6. Mexico
8.3.7. United States
8.4. Asia-Pacific
8.4.1. Overview
8.4.2. Market Sizing & Forecasting
8.4.3. Australia
8.4.4. China
8.4.5. India
8.4.6. Japan
8.5. Europe, Middle East & Africa
8.5.1. Overview
8.5.2. Market Sizing & Forecasting
8.5.3. France
8.5.4. Germany
8.5.5. Italy
8.5.6. Spain
8.5.7. United Kingdom
9. COMPETITIVE LANDSCAPE
9.1. 360iResearch FPNV Positioning Matrix for Global Biosimilars Market
9.2. Market Vendor Ranking Analysis for Global Biosimilars Market
9.3. Competitive News Feed Analysis for Global Biosimilars Market
10. COMPANY USABILITY PROFILES
10.1. Amgen Inc.
10.1.1. Overview
10.1.2. Strategy
10.1.3. SWOT
10.2. Biogen Inc.
10.2.1. Overview
10.2.2. Strategy
10.2.3. SWOT
10.3. Dr. Reddy's Laboratories Limited
10.3.1. Overview
10.3.2. Strategy
10.3.3. SWOT
10.4. Mylan N.V.
10.4.1. Overview
10.4.2. Strategy
10.4.3. SWOT
10.5. Pfizer Inc.
10.5.1. Overview
10.5.2. Strategy
10.5.3. SWOT
10.6. Sandoz International GmbH
10.6.1. Overview
10.6.2. Strategy
10.6.3. SWOT
10.7. AMEGA Biotech S.A.
10.8. Apotex Inc.
10.9. Biogen Inc.
10.10. Biosidus S.A.
10.11. Bioton S.A.
10.12. Dr. Reddy's Laboratories Limited
10.13. Innovent Biologics, Inc.
10.14. JHL Biotech, Inc.
10.15. LG Chem, Ltd.
10.16. Merck Sharp & Dohme Corp.
11. APPENDIX
11.1. Discussion Guide
11.2. Top Reports
11.2.1. Global Crane Rental Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025
11.2.2. Global Computer Vision Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025
11.2.3. Global Payment Gateway Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025
11.2.4. Global B2B Travel Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025
11.2.5. Global Varicose Vein Treatment Devices Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025
11.3. Author Details
